SEC Form 4 · accession 0001209191-18-008227
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Sachdev
Officer — EVP, CRO
Period of report
Feb 5, 2018
Accepted (ET)
Feb 7, 2018 · 6:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 5, 2018 | M | 1,942 | $86.52 | A | 41,105 | D | |
| Common Stock | Feb 5, 2018 | M | 2,578 | $77.31 | A | 43,683 | D | |
| Common StockF2,F3 | Feb 5, 2018 | S | 378 | $158.55 | D | 43,305 | D | |
| Common StockF3,F4 | Feb 5, 2018 | S | 700 | $159.93 | D | 42,605 | D | |
| Common StockF3,F5 | Feb 5, 2018 | S | 300 | $160.97 | D | 42,305 | D | |
| Common StockF3,F6 | Feb 5, 2018 | S | 300 | $161.93 | D | 42,005 | D | |
| Common StockF3,F7 | Feb 5, 2018 | S | 600 | $163.79 | D | 41,405 | D | |
| Common StockF3,F8 | Feb 5, 2018 | S | 2,242 | $164.93 | D | 39,163 | D | |
| Common Stock | holding | — | — | — | 882 | I | 401(k) | |
| Common Stock | holding | — | — | — | 12,215 | I | Held in Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F9 | $86.52 | Feb 5, 2018 | M | 1,942 | D | — | Feb 2, 2027 | Common Stock | 1,942 | 23,299 | D |
| Stock Option (Right to Buy)F10 | $77.31 | Feb 5, 2018 | M | 2,578 | D | — | Feb 4, 2024 | Common Stock | 2,578 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1.
- F10Fully vested.
- F2Open market sales reported on this line occurred at a weighted average price of $158.55 (range $158.24 to $159.09).
- F3Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $159.93 (range $159.46 to $160.47).
- F5Open market sales reported on this line occurred at a weighted average price of $160.97 (range $160.51 to $161.26).
- F6Open market sales reported on this line occurred at a weighted average price of $161.93 (range $161.70 to $162.39).
- F7Open market sales reported on this line occurred at a weighted average price of $163.79 (range $163.23 to $164.22).
- F8Open market sales reported on this line occurred at a weighted average price of $164.93 (range $164.31 to $165.06).
- F9The option vests in 16 quarterly installments from 2/3/2017.